At a glance
ClinicalIndex Comparison Record- ✓Idiopathic Parkinson's disease diagnosed according to UK Parkinson's Disease Society Brain Bank Criteria
- ✓Advanced levodopa-responsive PD with persistent motor fluctuations inadequately controlled by optimized medical treatment
- ✓Unified Dyskinesia Rating Scale (UDysRS) Total score ≥30
- ✕Prior treatment with Levodopa-Carbidopa Intestinal Gel (LCIG)
- ✕Uncertain PD diagnosis or suspicion of parkinsonian syndrome (secondary parkinsonism, parkinson-plus syndrome, other neurodegenerative disease)
- ✕Prior neurosurgery for Parkinson's disease treatment
- ✕Contraindications to levodopa (e.g., narrow angle glaucoma, malignant melanoma)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Randomized 12 Week Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease DYSCOVER (DYSkinesia COmparative Interventional Trial on Duodopa VERsus Oral Medication)
In Brief
A Phase 3 clinical trial evaluating Optimized antiparkinsonian treatment, Levodopa-Carbidopa Intestinal Gel (LCIG), and 3 other interventions for Parkinson's Disease (PD). Completed, enrolled 63 participants across 28 sites in 7 countries.
Detailed Summary
The primary objective of this study was to examine the effect of levodopa-carbidopa intestinal gel (LCIG) compared with optimized medical treatment (OMT) on dyskinesia in participants with advanced Parkinson's disease (PD).
Study Details
Timeline
Interventions
Dose levels of prescribed antiparkinsonian medications were individually optimized to their maximum therapeutic effect.
Dose levels were individually optimized.
(manufactured by Smiths Medical)
(PEG tube)
(J-tube)